Speed Bump
Horizon's Tepezza Shortage Just a Speed Bump -- Market Talk
10:41 am ET December 17, 2020 (Dow Jones) Print
1040 ET - Analysts at Piper Sandler aren't worried about the looming supply disruption of Horizon Therapeutics' Tepezza, calling it a speed bump on the drug's road to blockbuster status. Horizon says a focus on production of coronavirus vaccines at Catalent, its contract manufacturer of Tepezza, will lead to a short-term disruption in supply of the treatment of thyroid eye disease. Piper says that while the shortage "will undoubtedly be significant," it will also be short-lived and won't get in the way of Tepezza emerging as a multi-billion-dollar franchise. The analysts reiterate their overweight rating
Don't understand why investors (including some on this board) get so shaken up about an obviously undeserved, temporary hit to pps. I agree with PS wholeheartedly, although their $123 target might be a little low.
Having been through these wringers many a time, it is "a temporary condition (Rocky)." I've also been on the wrong side of serious problems that developed with drugs after they were approved, like Elan's Tysabri when it showed that some patients developed PML. Lost $1M overnight on that one. No such issues with either T or K, so the current swoon is just the faint of hearts.
"Speed Bump" was my call sign in the Navy, so I heartily endorse the title of PS's piece.